Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02826434|
Recruitment Status : Active, not recruiting
First Posted : July 11, 2016
Last Update Posted : December 22, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study is studying the safety, tolerability, and immune response of these treatments.
The names of the study interventions involved in this study are:
- PVX-410 Vaccine
- Durvalumab (MEDI4736)
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Biological: PVX-410 Biological: Durvalumab Drug: Hiltonol||Phase 1|
This research study is a Phase Ib clinical trial, which tests the safety of an investigational intervention and also tries to better understand how the investigational intervention affects the body. "Investigational" means that the intervention is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved PVX-410 and Durvalumab as a treatment for any disease.
- Durvalumab is a protein that affects your immune system by blocking the PD-L1 pathway. The PD-L1 pathway controls the body's natural immune response, but tumors can interrupt this pathway and partially resist or escape the immune system. By blocking the PD-L1 pathway, Durvalumab may help the immune system identify and catch tumor cells.
- PVX-410 is an investigational vaccine that is being developed to treat multiple myeloma and triple negative breast cancer.
- In this research study, the investigators are studying the body's immune response to the PVX-410 study vaccine in combination with Durvalumab. This study will help researchers understand if the vaccine and Durvalumab can work together to help the body's immune system recognize triple negative breast cancer. The investigators are also studying the safety of the PVX-410 vaccine alone and together with the Durvalumab.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer|
|Actual Study Start Date :||August 2016|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||September 2023|
Experimental: PVX-410 and Durvalumab
Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.
This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
This is an intravenous infusion of a monoclonal antibody.
Other Name: MEDI4736
This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
Other Name: poly-ICLC
- Dose Limiting Toxicity Rate of PVX-410 in Combination With Durvalumab [ Time Frame: 4 Weeks ]To assess the safety of the vaccine and PDL1 inhibitor.
- Immune Response Rate of cluster designation 8 (CD8)+ Cytotoxic T Lymphocytes (CTLs) to Vaccine-Specific Peptides [ Time Frame: 14 weeks from first dose ]To assess the response of the immune system after treatment with the vaccine and PDL1 inhibitor.
- Disease-Free Survival [ Time Frame: Up to approximately 5 years ]The duration of time from the complete remission until disease progression or death, whichever occurs first..
- Adverse events according to Common Toxicology Criteria for Adverse Events (CTCAE 4.0) will be assessed for the PVX-410 vaccine regimen alone versus PVX-410 vaccine regimen plus durvalumab [ Time Frame: From the start of treatment until 30 days after the end of treatment, up to approximately 14 weeks ]Adverse events will be assessed using Common Toxicology Criteria for Adverse Events (CTCAE 4.0)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Written informed consent and any locally-required authorization obtained from the patient prior to performing any protocol-related procedures, including Screening evaluations.
- Females, ≥18 years at time of study entry.
- HLA-A2 positive by deoxyribonucleic acid (DNA) sequence analysis (by history or as part of this study).
- Histopathological diagnosis of triple negative breast cancer(TNBC) (ductal, lobular, mixed or metaplastic), defined as estrogen receptor (ER)<1%, progesterone receptor (PR)<1%, and Human Epidermal growth factor Receptor 2 (HER2) negative according to American Society of Clinical Oncology/College of American Pathologists guidelines by local testing according to institutional standards. For tumors with equivocal interpretation of receptor status (e.g. "weak" or "faint" staining, the Principal Investigator will have final determination of triple negative status.
Completed all planned therapy for Stage II or III TNBC (American Joint Committee on Cancer, 7th Edition) meeting the following guidelines:
- received neoadjuvant chemotherapy with residual invasive disease at surgery and/or completed adjuvant chemotherapy with or without radiation. (The patient may have had adjuvant and/or neoadjuvant chemotherapy for their disease). Adjuvant/neoadjuvant chemotherapy regimens must include at least 4 cycles of a standard chemotherapy regimen, and generally this should include one of the generally accepted standard regimens (including but not limited to: Adriamycin/Cytoxan-Taxol, Taxotere/Cytoxan, Adriamycin/Cytoxan, or Cytoxan/Methotrexate/Fluorouracil). For patients who received their standard chemotherapy as part of a clinical trial, the regimen should include at least 4 cycles of therapy.
- All planned radiation therapy surgery for the treatment of the current cancer should be complete (not including plastic or reconstructive surgery).
- Patients with local-regional recurrence without evidence of distant metastases (no definite stage IV disease) who are treated with curative intent may be eligible following completion of all surgery and/or chemotherapy and/or radiotherapy. Such patients must have no evidence of residual disease by standard clinical and radiological examination (per Investigator discretion) following completion of curative intent treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (see Appendix B).
Adequate normal organ and marrow function as defined below:
- Hemoglobin ≥9.0 g/dL.
- absolute neutrophil count (ANC) ≥1.5 109/L (≥1500 per mm3).
- Platelet count ≥100 109/L (>100,000 per mm3).
- Serum bilirubin ≤1.5 institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology).
- aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤2.5 ULN.
- gamma-glutamyltransferase (GGT), lactate dehydrogenase (LDH), and alkaline phosphatase ≤2.5 ULN.
- Serum creatinine clearance >40 mL/min by the Cockcroft-Gault formula 72 or by 24-hour urine collection for determination of creatinine clearance:
Creatinine Clearance (mL/min) = Weight (kg) x (140 - Age) 0.85 72 x serum creatinine (mg/dL)
- Negative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), and hepatitis C.
- Female patients must either be of non-reproductive potential (i.e. post-menopausal by history of age ≥60 years old and no menses for 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test (β-human chorionic gonadotropin (HCG)) at the Screening visit. (If Screening visit pregnancy test was completed within 7 days of first treatment visit it does not need to be repeated. Patients with a negative pregnancy test at Screening beyond 7 days prior to treatment, but who otherwise meet all other criteria, may be registered to study but must have a repeat negative serum pregnancy test within 7 days of treatment and such testing may be done on day of first treatment prior to administration).
- If not postmenopausal or surgically sterile, study patients must be willing to practice at least one of the following methods of birth control for at least a menstrual cycle before and after study drug administration: (1) Total abstinence from sexual intercourse with a male; (2) Sexual intercourse with vasectomized male partner; (3) Other acceptable forms of birth control (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicide or cream); (4) Use of an intrauterine contraceptive device.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
- Previous enrollment in the present study.
- Receipt of the last dose or treatment of anti-cancer therapy for the current cancer (chemotherapy, radiotherapy, surgery, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) ≤4 weeks (6 weeks for nitrosoureas or mitomycin C) or >6 months prior to first dose of study drug.
- Any unresolved clinically significant treatment related toxicity of ≥Grade 1 intensity, as assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), from previous anti-cancer therapy. Patients with irreversible toxicity (eg, hearing loss, peripherally neuropathy) or reversible toxicity (eg, alopecia) that is not reasonably expected to be exacerbated by the investigational product and is not expected to interfere with study participation may be included.
- Participation in another clinical study with an investigational product during the previous 4 weeks.
- Any previous treatment with a programmed cell death protein 1 (PD1) or PD-L1 inhibitor, including durvalumab.
- Stage IV disease, confirmed by biopsy or unequivocal radiographic evidence (note: staging scans are not required, but should be performed at treating physician discretion in accordance with standard guidelines).
- Mucinous or tubal histology or other good prognosis histology.
- Ongoing or planned systemic anti-cancer therapy or radiation therapy.
- Pregnant or nursing.
- Known hypersensitivity to any component of the investigational product (PVX-410, durvalumab, or any excipient).
- Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction.
- Active or prior documented active autoimmune disease that has required systemic treatment. Note: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
- Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic (oral or iv) corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
- History of primary immunodeficiency.
- History of allogeneic organ transplant.
- Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have evidence of acute or chronic hepatitis B, hepatitis C or HIV)
- Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent.
- History or clinical evidence of any surgical or medical condition which the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating (eg, active or clinically significant history of disease involving a major organ system-vascular, cardiac, pulmonary, hepatic, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine or immunodeficiency, autoimmune or clinically significant active psychiatric disorders).
- Known history of previous clinical diagnosis of tuberculosis
- Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
- Weight < 30 kg
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02826434
|United States, Florida|
|Lee Moffitt Cancer Center and Research Institute|
|Tampa, Florida, United States, 33607|
|United States, Massachusetts|
|Massachusetts general Hospital|
|Boston, Massachusetts, United States, 02114|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02115|
|Dana Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|United States, New York|
|New York University School of Medicine|
|New York, New York, United States, 10016|
|Principal Investigator:||Steven Isakoff, MD, PhD||Massachusetts General Hospital|
|Responsible Party:||Steven J Isakoff, MD, PhD, Steven Isakoff MD PhD, Massachusetts General Hospital|
|Other Study ID Numbers:||
|First Posted:||July 11, 2016 Key Record Dates|
|Last Update Posted:||December 22, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
triple negative breast cancer
Triple Negative Breast Neoplasms
Neoplasms by Site
Antineoplastic Agents, Immunological
Physiological Effects of Drugs